Low Libido in Women (HSDD)

Low libido in women becomes a recognized medical concern — hypoactive sexual desire disorder, or HSDD — when a persistent or recurrent lack of sexual desire and sexual thoughts causes genuine personal distress for at least six months and is not better explained by another illness, medication, or relationship problem. A low or fluctuating sex drive by itself is normal and extremely common; HSDD is specifically the version that bothers the person experiencing it, and it is a treatable condition rather than a character flaw or an inevitable part of aging.

What is low libido in women (HSDD)?

Sexual desire in women is not a simple on/off switch. It is shaped by biology (hormones, neurotransmitters such as dopamine and serotonin, general health), psychology (mood, body image, past experiences, stress), and relationship and cultural context. Because of this, "normal" desire spans an enormous range, and desire naturally rises and falls across the menstrual cycle, pregnancy, the postpartum period, perimenopause, and life circumstances.

Hypoactive sexual desire disorder (HSDD) is the clinical label for low desire that is both persistent and *distressing*. The distress criterion is essential: a woman with little interest in sex who is perfectly content is not considered to have a disorder. HSDD describes a deficiency or absence of sexual fantasies and desire for sexual activity that causes marked personal distress or interpersonal difficulty (NIH/StatPearls).

The terminology has shifted over time, which is a frequent source of confusion. Historically, HSDD carried the diagnostic code ICD-10 F52.0 ("lack or loss of sexual desire"). In 2013, the *DSM-5* merged low desire and low arousal in women into a single combined diagnosis called Female Sexual Interest/Arousal Disorder (FSIAD). Many sexual-medicine specialists disagreed with collapsing the two, so the International Society for the Study of Women's Sexual Health (ISSWSH) and the International Consultation in Sexual Medicine published a separate nomenclature that retains HSDD and female sexual arousal disorder as distinct conditions. As a result, both "HSDD" and "FSIAD" are used in current practice and research, and they overlap heavily. HSDD can also be classified as *generalized* (occurring in all situations) or *situational*, and as *lifelong* (present since first sexual experiences) or *acquired* (developing after a period of normal desire).

Low desire is among the most commonly reported sexual concerns in women. Survey data have long indicated that a substantial minority of women report low sexual desire, but only a portion of those women also experience the distress required for a diagnosis of HSDD — which is why distress, not the desire level alone, defines the disorder (NIH/StatPearls; ISSWSH).

What causes low libido in women, and who is at risk?

HSDD is best understood as *multifactorial* — usually several contributors act together rather than a single cause. Identifying the mix matters, because treatment follows the cause. Recognized contributors include:

Biological and hormonal factors

• Menopause and perimenopause. Declining estrogen can cause vaginal dryness and painful sex (genitourinary syndrome of menopause), which secondarily lowers desire. The role of testosterone is more nuanced — a single blood testosterone level does *not* reliably diagnose or predict HSDD (Endocrine Society; ISSWSH 2021 guideline).
• Hormonal and reproductive transitions such as pregnancy, the postpartum period, and breastfeeding.
• Chronic medical conditions including diabetes, thyroid disease, cardiovascular disease, chronic pain, and cancer.
• Pelvic and gynecologic conditions that make sex uncomfortable, such as endometriosis, vaginismus, or vulvodynia.

Medications and substances

A number of widely used drugs can blunt desire. The most frequently implicated are selective serotonin reuptake inhibitors (SSRIs) and other antidepressants, which commonly reduce libido and delay orgasm. Hormonal contraceptives, certain blood-pressure medications (such as beta-blockers), opioids, antipsychotics, and heavy alcohol use can also contribute (NIH/StatPearls).

Psychological factors

Depression, anxiety, chronic stress, fatigue, poor sleep, negative body image, and a history of sexual trauma or abuse are strongly associated with low desire. Depression and HSDD frequently coexist, and either can worsen the other.

Relationship and contextual factors

Relationship conflict, poor communication, mismatched desire between partners, a partner's sexual dysfunction, lack of privacy, and life stressors (caregiving, work, finances) are among the most common real-world drivers of acquired, situational low desire.

Who is at greatest risk? Women in midlife and the menopausal transition, those taking antidepressants or other desire-lowering medications, women with depression or anxiety, those with chronic illness or pelvic pain, and women experiencing significant relationship strain. Importantly, HSDD occurs in premenopausal women as well, and is not limited to any single age group.

What are the symptoms of HSDD?

HSDD is defined by what is *absent or reduced*, combined with the *distress* it causes. Typical features include:

• Few or no sexual thoughts or fantasies.
• Little or no interest in initiating sexual activity, and reduced receptivity to a partner's advances.
• Loss of sexual desire that was previously present (in acquired cases), or a sense of never having had much desire (in lifelong cases).
• Reduced pleasure or excitement during sexual activity in some women (this overlaps with the arousal component captured by FSIAD).
• Personal distress, frustration, low self-esteem, or relationship strain stemming from the lack of desire.

The defining symptom is not "low desire" in isolation but the *combination of low desire with meaningful distress*. A woman who has little interest in sex and feels fine about it does not have HSDD. When low desire causes worry, guilt, conflict with a partner, or unhappiness, it crosses into the territory worth evaluating.

How is HSDD diagnosed?

There is no blood test, scan, or single number that diagnoses HSDD. Diagnosis is clinical — based on a careful history and the patient's own report of distress (Endocrine Society; ISSWSH).

Diagnostic criteria

Across the major frameworks, the core elements are consistent. The desire problem must be:

1. Persistent or recurrent — present for at least 6 months.
2. Frequent — occurring most or all of the time (in the *DSM-5* FSIAD criteria, several of the individual symptom items, such as reduced excitement/pleasure or genital sensation, are specified as occurring in approximately 75%–100% of sexual encounters).
3. Distressing — causing clinically significant personal distress.
4. Not fully explained by another mental disorder, a medication or substance, a general medical condition, severe relationship distress (such as partner violence), or another stressor.

The *DSM-5* FSIAD criteria require a reduction in sexual interest/arousal indicated by at least three of six features (such as reduced interest, reduced erotic thoughts, reduced initiation, reduced excitement, reduced response to sexual cues, or reduced genital sensation).

Screening tools

Clinicians often use brief validated questionnaires to structure the conversation, including the Decreased Sexual Desire Screener (DSDS) — a short five-item tool designed specifically to help identify generalized acquired HSDD — and the Female Sexual Function Index (FSFI), a longer questionnaire scoring six domains (desire, arousal, lubrication, orgasm, satisfaction, and pain). These tools support, but do not replace, clinical judgment.

What testing is actually for

Lab work is used not to "prove" HSDD but to identify reversible contributors and rule out mimics. Depending on the history, a clinician may check thyroid function, prolactin, blood glucose, or evaluate for iron deficiency or depression. Because no testosterone threshold defines female sexual dysfunction, routine testosterone testing is not recommended to diagnose HSDD, although a clinician may measure it before considering testosterone therapy and to exclude excessively high levels (Endocrine Society; ISSWSH 2021). A pelvic exam helps detect dryness, atrophy, or pain conditions contributing to the problem.

How is HSDD treated?

Treatment is individualized and follows a stepwise, cause-directed approach. The first step is almost always to address reversible contributors — and many women improve without prescription medication.

Step 1: Lifestyle, education, and addressing contributors

• Optimize sleep, manage stress, and treat depression or anxiety. Because mood disorders and fatigue heavily suppress desire, treating them often restores libido.
• Review medications. If an SSRI is suspected, a clinician may adjust the dose, switch to an antidepressant less associated with sexual side effects (such as bupropion), or add a strategy to counter the effect — always under medical supervision, never by stopping a prescribed drug abruptly.
• Treat painful sex and vaginal dryness. Over-the-counter vaginal moisturizers and lubricants can make sex comfortable again; for menopausal dryness, prescription local (vaginal) estrogen is highly effective and addresses a common reversible cause.
• Relationship and communication work, including addressing mismatched desire and partner factors.

Step 2: Psychotherapy and counseling

Evidence-based talk therapies are a cornerstone of HSDD care and are often first-line. Sex therapy, cognitive behavioral therapy (CBT), and mindfulness-based interventions have shown benefit for desire and sexual distress, and couples counseling helps when relationship factors are central. These approaches can be used alone or alongside medication.

Step 3: Prescription options

Two medications are FDA-approved specifically for acquired, generalized HSDD:

• Flibanserin (Addyi) — a daily oral medication that acts on serotonin, dopamine, and norepinephrine pathways in the brain. It was first approved in 2015 for premenopausal women; in December 2025 the FDA expanded its approval to include postmenopausal women younger than 65. In trials, it produced modest improvements in desire and in the number of satisfying sexual events. Key cautions: it must be taken at bedtime, it carries warnings about low blood pressure and fainting, and these risks are increased by alcohol (the label advises stopping alcohol at least 2 hours before the bedtime dose) and by certain interacting drugs (FDA label).
• Bremelanotide (Vyleesi) — an on-demand injection under the skin, used before anticipated sexual activity, approved in 2019 for premenopausal women with HSDD. It activates melanocortin receptors and modestly improved desire and reduced distress in trials. Common side effects include nausea, flushing, and headache (FDA label).

Both drugs target *desire* and are not aimed at arousal or orgasm, and the average benefit over placebo is real but modest.

Off-label hormonal therapy. For postmenopausal women with HSDD not explained by other factors, major societies support a trial of systemic transdermal testosterone dosed to female physiologic ranges. The 2019 Global Consensus Position Statement and the 2021 ISSWSH clinical practice guideline conclude that, for this group, testosterone provides a *moderate* therapeutic benefit for sexual desire, arousal, orgasm, and pleasure (Global Consensus Position Statement 2019; ISSWSH 2021; Endocrine Society). Important caveats: there is no testosterone product FDA-approved for women in the United States, so dosing relies on careful use of male formulations at a fraction of the dose with monitoring; long-term safety has not been established; and testosterone is not recommended for premenopausal women for this purpose, nor is it endorsed for symptoms other than HSDD.

Treating menopausal symptoms with menopausal hormone therapy can indirectly improve desire when dryness and hot flashes are the underlying problem, but standard estrogen therapy is not itself a treatment for HSDD.

Can HSDD be prevented or managed long-term?

HSDD cannot always be prevented, but several strategies reduce risk and support long-term sexual well-being:

• Treat depression, anxiety, and sleep problems early, and discuss sexual side effects when starting medications so alternatives can be considered.
• Maintain open communication with a partner and address relationship strain before it erodes intimacy.
• Manage chronic conditions such as diabetes and address pelvic pain or vaginal dryness promptly.
• Limit heavy alcohol use and stay physically active, which supports mood, energy, and body image.
• Expect and normalize fluctuation. Desire naturally varies with stress, hormones, and life stage; understanding this prevents normal dips from becoming a source of distress.

Long-term management is often a combination approach — for example, sex therapy plus treating dryness plus adjusting a contributing medication — and may need periodic adjustment as circumstances change.

When should you see a doctor?

Consider talking to a clinician (a primary care physician, gynecologist, or a sexual-medicine or menopause specialist) when:

• Low desire persists for several months and is distressing to you or straining your relationship.
• Low libido began after starting a new medication (especially an antidepressant) or after a hormonal change such as childbirth or menopause.
• Sex has become painful, or you have new vaginal dryness, bleeding, or pelvic pain.
• Low desire is accompanied by symptoms of depression (persistent low mood, loss of interest, hopelessness) or thoughts of self-harm — these warrant prompt attention.

Red flags that deserve urgent evaluation include a sudden, unexplained loss of desire together with other new symptoms (such as fatigue, unexplained weight change, hair loss, or galactorrhea/breast milk discharge), which can point to a thyroid or pituitary problem, and any low desire occurring in the context of relationship abuse or coercion, which requires a safety-focused response rather than a medication.

What is the outlook for women with HSDD?

The outlook is generally favorable, particularly when contributing factors are identified and addressed. Because HSDD is so often multifactorial, the single most encouraging fact is that many cases improve once reversible contributors — a depression-causing medication, untreated mood disorder, painful dryness, relationship conflict — are corrected, sometimes without any HSDD-specific drug.

For women who need more, the combination of psychotherapy, treatment of underlying conditions, and (where appropriate) FDA-approved medication or, in postmenopausal women, testosterone therapy improves desire and reduces distress for a meaningful proportion of patients. The benefits of the drug therapies are real but modest on average, so realistic expectations and a willingness to try a combination of strategies tend to produce the best results. HSDD is a chronic, fluctuating condition for some women and a temporary, fully resolvable problem for others; with appropriate care, most women can expect meaningful improvement in satisfaction and well-being.

Frequently asked questions

Is low libido just a normal part of aging or menopause? Some decline in desire is common with age and hormonal change, and a lower libido that does not bother you is not a disorder. It becomes HSDD only when the lack of desire is persistent *and* causes you distress. Distressing low desire at any age is worth evaluating, because it is often treatable — frequently by addressing dryness, mood, medications, or relationship factors rather than by accepting it as inevitable.

Is there a "female Viagra"? Not in the way the nickname implies. Sildenafil (Viagra) increases blood flow and treats erectile dysfunction; it does not reliably address *desire* in women. The medications approved specifically for low desire in women — flibanserin (Addyi) and bremelanotide (Vyleesi) — work on brain chemistry, not blood flow, and target desire rather than arousal or orgasm.

Could my antidepressant be lowering my sex drive? Yes — reduced libido is one of the most common side effects of SSRIs and some other antidepressants. Do not stop your medication on your own. A clinician can lower the dose, switch to an antidepressant less likely to affect desire (such as bupropion), or add a strategy to counter the effect, while keeping your mood well treated.

Will testosterone help my low libido? For postmenopausal women with HSDD that is not explained by other causes, transdermal testosterone at female physiologic doses offers a moderate benefit, according to international guidelines. However, no testosterone product is FDA-approved for women in the U.S., long-term safety is not established, and it is not recommended for premenopausal women for this purpose. A single testosterone blood level cannot diagnose HSDD. Any trial should be supervised, with monitoring.

How is HSDD actually diagnosed — is there a test? There is no lab test that diagnoses HSDD. The diagnosis is based on your history and your report of distress, sometimes supported by brief questionnaires such as the Decreased Sexual Desire Screener (DSDS). Blood tests (thyroid, prolactin, glucose) are used to find treatable contributors and rule out other conditions, not to confirm the diagnosis.

*This page is for general education and is not medical advice. Talk with a qualified clinician about your individual situation, especially before starting, stopping, or changing any medication.*